Why the study?
Does tissue-type plasminogen activator (t-PA) improve outcomes compared to streptokinase in patients with acute myocardial infarction?
Does tissue-type plasminogen activator (t-PA) improve outcomes compared to streptokinase in patients with acute myocardial infarction?
The GUSTO trial results strongly suggest that t-PA is more effective than streptokinase for treating acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
May support t-PA over streptokinase in AMI; leaves open need for updated comparisons with modern reperfusion.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
J. M. Gore (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: